Handheld devices that can detect the telltale signs of peripheral neuropathy in people with diabetes could have another important function—predicting the risk that they will die within the next few ...
ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...
A $3.6 million award from the National Institutes of Health will allow neurosurgical, neurology and neuroscience researchers at The Ohio State University Wexner Medical Center and College of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback